Dr. Gilmore O’Neill is the current CEO of Editas Medicine, having taken on the role in June 2022. He holds a Ph.D. in Biomedical Engineering from the University of California, San Diego, which lays a solid foundation for his work...

Dr. Gilmore O’Neill is the current CEO of Editas Medicine, having taken on the role in June 2022. He holds a Ph.D. in Biomedical Engineering from the University of California, San Diego, which lays a solid foundation for his work in the biotechnology sector. O’Neill previously held significant positions at Sarepta Therapeutics and Biogen, indicating that he has been active in the biopharma landscape for a long time. His leadership approach is closely linked to performance, as his recent compensation reflects increasing company goals, including an impressive annual bonus that rewards achieving corporate objectives. In 2023, he earned a total compensation of approximately $2.4 million, largely from performance-based stock units that vest based on reaching crucial research and development milestones. This aligns his interests with those of the shareholders, showcasing a results-driven philosophy. His current stock portfolio also highlights a commitment to the company's success, as he holds a significant number of shares. O’Neill is not just a figurehead; he embodies the biotech spirit of innovation and strategic growth. Under his guidance, Editas is positioned to impact genetic medicine and gene editing, matching the excitement of a rapidly evolving field.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Editas Medicine CEOs

E

Gilmore O’Neill

CEO of Editas Medicine

Education

Ph.D. in Biomedical Engineering from the University of California, San Diego.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

CEO of Editas Medicine for

3 years 0 months (Jun 2022 - Present)

Previous Experience

Various leadership roles in biotechnology and healthcare.

Rivals

Competitors/colleagues of Gilmore O’Neill

B

John Evans

CEO of Beam Therapeutics

2023 Compensation

Stock

$0.00

Salary

$685.00K

Bonus

$431.55K

Other

$17.68K

Total Holdings

$24.88M

Holdings

See how much did Gilmore O’Neill make over time.

Dr. Gilmore O’Neill holds a substantial stake in Editas Medicine, with performance-based stock units (PSUs) that are key to his wealth. As of 2023, he had about 216,637 PSUs tied to specific R&D milestones, highlighting his commitment and belief in...

Dr. Gilmore O’Neill holds a substantial stake in Editas Medicine, with performance-based stock units (PSUs) that are key to his wealth. As of 2023, he had about 216,637 PSUs tied to specific R&D milestones, highlighting his commitment and belief in the company's prospects. His stock awards align with corporate performance, ensuring that he benefits from the company's success. The current value of his holdings can be seen as both a bet on his leadership and a reflection of his expertise. In 2023 alone, O’Neill's wealth from stock options and awards around Editas reached approximately 2.2 million, evidencing a solid performance and the company's trajectory. It’s noteworthy that his wealth is directly tied to the achievement of ambitious goals, making him a significant player in the biotech space.

Loading...

Insider Trading

See recent insider trades of Gilmore O’Neill.

No insider trades found for this CEO.

Compensation History

See how much did Gilmore O’Neill make over time.

Dr. Gilmore O’Neill’s compensation package reflects a performance-oriented approach that is common in the biotech industry. In 2023, his total compensation amounted to approximately $2.4 million, broken down into salary, bonus, and the value of vested stock units. His salary was about $641,092, with a performance bonus of $392,537 tied to corporate goal achievements, demonstrating his accountability to shareholders. Notably, O’Neill’s compensation also included benefits from performance-based stock awards that came to roughly $2.2 million. These stock units emphasize that his financial success is closely linked to the company's performance in the dynamic biotech landscape. For 2022, he initially earned $9 million, showcasing a major earning potential based on performance metrics. He is therefore incentivized to push Editas towards growth and innovation, aligning his interests closely with those of the company's investors.

Year

2023

Total Compensation

$3.24M

Salary

$641.09K

Board Justification

The compensation philosophy is designed to attract and retain qualified executives, motivate them to achieve business goals, and reward them for performance. It emphasizes a significant portion of performance-based compensation.

Bonus

$392.54K

Board Justification

The annual performance-based cash bonus for Dr. O’Neill was determined solely based on the achievement of corporate goals and his target bonus amount, as determined by our Board, and pursuant to the terms of his offer letter.

Other

$7.29K

Board Justification

Other compensation includes life insurance premiums and 401(k) matching contributions.

Restricted Stock

$2.19M(216.64K RSU)

Board Justification

The stock awards granted to Dr. O’Neill that vested in 2023 were performance-based restricted stock units (PSUs) that vest upon the achievement of certain research and development milestones.

Performance Metrics

The performance metrics for Dr. O’Neill's compensation were based on corporate performance goals, with a corporate achievement percentage of 102% for 2023.

Other Editas Medicine CEOs

Here are other CEOs of Editas Medicine

James C. Mullen

Ex-CEO of Editas Medicine

February 2021 - June 2022